Treatment outcomes in ANCA-associated vasculitis: Determinants of efficacy and toxicity

Hessels, A., 2019, [Groningen]: Rijksuniversiteit Groningen. 163 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard


  • Title and contents

    Final publisher's version, 660 KB, PDF document

  • Chapter 1

    Final publisher's version, 1 MB, PDF document

  • Chapter 2

    Final publisher's version, 967 KB, PDF document

  • Chapter 3

    Final publisher's version, 2 MB, PDF document

  • Chapter 4

    Final publisher's version, 1 MB, PDF document

  • Chapter 5

    Final publisher's version, 640 KB, PDF document

  • Chapter 6

    Final publisher's version, 910 KB, PDF document

  • Chapter 7

    Final publisher's version, 947 KB, PDF document

  • Chapter 8

    Final publisher's version, 594 KB, PDF document

  • Nederlandse samenvatting

    Final publisher's version, 530 KB, PDF document

  • Dankwoord

    Final publisher's version, 514 KB, PDF document

  • About the author

    Final publisher's version, 507 KB, PDF document

  • Complete thesis

    Final publisher's version, 5 MB, PDF document

  • Propositions

    Final publisher's version, 186 KB, PDF document

  • Arno Hessels
In the last 50 years, ANCA-associated vasculitis changed from a lethal disease to a chronic disease with a much better life expectancy. This has led to new challenges in its treatment. For example, patients still experience frequent relapses of vasculitis, resulting in damage from disease activity and adverse effects of treatment. As a result, patients experience limitations in daily activities, even after successful treatment. A personalised treatment might improve the balance between efficacy and toxicity of treatment. In this thesis, we show that several genes affect efficacy and toxicity of drugs used for vasculitis. If this knowledge is expanded on in independent research, we will be closer to a personalised treatment.

We have shown that classification based on ANCA type is important, although some geographical differences cannot be explained by ANCA type alone. Patients receiving azathioprine maintenance therapy have an increased risk of developing hypersensitivity for this drug than previously assumed. Its symptoms strongly resemble an infection or disease relapse. It is important to be aware of this adverse effect, since it can simply be treated by stopping and replacing azathioprine. Lastly, it is important to study a rehabilitation or training programme to improve daily functioning. Because every vasculitis patient is unique, among other reasons because of differences in organ involvement, the individual patient should be considered instead of developing one training programme for all vasculitis patients.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date20-Mar-2019
Place of Publication[Groningen]
Print ISBNs978-94-6375-159-9
Electronic ISBNs978-94-034-1493-5
Publication statusPublished - 2019

Download statistics

No data available

ID: 76684282